With PCOS, She Stopped a GLP-1 Before Trying for Pregnancy

The notebook was open on the kitchen table when Amara took her last dose in May 2025. She had written the month at the top of the page, then the words “last dose” beneath it. The next line stayed empty.

Amara is a composite, drawn from accounts of people navigating PCOS, GLP-1 medications, and pregnancy planning. In her life, she is a 29-year-old newlywed in Atlanta who keeps medical information in an ordinary notebook because portals change and lab papers disappear. The first pages hold years of irregular cycles and rising glucose measurements. Later pages show what changed during 14 months on a GLP-1 medication prescribed for metabolic health in the context of PCOS.

Her A1C had moved from 6.2% to 5.6%. Her triglycerides fell from 218 to 146.

She lost 27 pounds, though she disliked how quickly other people treated that number as the whole story. What mattered to her was that her primary care doctor no longer paused over the same lab results, and that she could walk through her neighborhood without thinking about how tired she felt.

The notebook had become a handrail. It held evidence from a body she had spent years being told to manage better, even when she was following the plans given to her and still watching the numbers move in the wrong direction.

Then she and her husband decided they wanted to try for a baby.

The appointment that changed the plan

At a preconception visit, Amara expected a conversation about prenatal vitamins and cycle tracking. Instead, much of the visit centered on the GLP-1 medication.

These medications are commonly prescribed for type 2 diabetes or chronic weight management, depending on the particular drug and the person’s circumstances. Some people with PCOS receive them to address metabolic concerns such as insulin resistance or higher body weight, although GLP-1 medications are not approved as a treatment for PCOS itself and are not fertility drugs.

Pregnancy changed the risk calculation. Human pregnancy data remain limited, and product labeling advises against using GLP-1 medications during pregnancy. The recommended interval between stopping and trying to conceive varies by medication. After reviewing Amara’s prescription and health history, her specialist set an eight-week interval before she and her husband would begin trying.

Amara understood the explanation. She was also angry.

The anger surprised her because she wanted the pregnancy plan. She had chosen it. Still, the medication had helped steady health markers she had struggled with since her early twenties, and stopping felt less like clearing an obstacle than surrendering something she had worked hard to reach.

Her husband listened while she tried to describe both feelings without forcing them into agreement. She wanted a child. She did not want her health to worsen. Neither statement canceled the other.

At home, she opened the notebook to the page where she had tracked each monthly dose and the lab results that followed. She copied the eight-week interval into the margin. Then she placed the medication box in a cabinet until she could ask the pharmacy how to dispose of what remained.

What the pause felt like

For the first week, very little happened. That almost made it harder.

Amara had prepared for an abrupt change, yet her days looked familiar. She went to work, ate dinner with her husband, and walked after the heat eased. Without a dramatic physical event to occupy her, she noticed the emotional one. She felt grief, followed by embarrassment about feeling grief over a prescription.

There was no failure in that reaction. A medication can be practical and still come to represent relief, particularly after years of appointments in which improvement seemed to depend on trying harder at things a person was already trying to do.

By the third week, Amara noticed that hunger arrived earlier in the afternoon. She wrote it down without deciding what it meant. Her specialist had told her that appetite and weight could change after stopping, but one person’s experience could not predict another’s, and a shift did not prove that every change came from the medication pause.

Her period was nine days later than the previous one. Irregular cycles had been part of her life with PCOS long before the GLP-1, so she resisted making the late period into a verdict. Still, she entered the date in the notebook and drew a small box around it.

The plan included follow-up lab work three months after stopping. That timing meant she would begin trying to conceive before she had a new set of numbers, unless pregnancy or another health concern changed the plan. She disliked the gap. Her clinicians could explain why the schedule was reasonable in her case, but they could not remove the uncertainty inside it.

She began checking the notebook more often, as if a past A1C could reassure her about a future one. Some evenings she left it closed.

A different kind of preparation

During those eight weeks, Amara had appointments with her primary care doctor and the clinician overseeing her preconception care. They reviewed her prescriptions and discussed how her PCOS and metabolic history might be followed if she became pregnant. The focus stayed on her particular record rather than on a promise that one plan would work for every person with PCOS.

There was also an insurance concern. The authorization for her GLP-1 medication would expire during the pause, and no one could guarantee that the same coverage would be available if she sought to restart it later. Her specialist’s office documented why treatment had been prescribed and what her lab results had shown, then told her they would address a new authorization if it became relevant.

Amara wrote “coverage unknown” in the notebook. She hated those words more than she expected. The medical pause was deliberate, but the insurance uncertainty was not, and it made a personal decision feel partly controlled by a future reviewer she would never meet.

She and her husband had married seven months earlier. Their apartment still held unopened wedding gifts, and pregnancy planning had once seemed like it would belong to the happy part of being newly married. Instead, some nights ended with her reading old lab reports while he cleared the table.

They did not turn every dinner into a health discussion. That mattered. They went to a cousin’s cookout and spent a Saturday choosing shelves for the living room. She laughed.

She worried. Ordinary life made room for both.

Near the end of the eight weeks, Amara’s fear sharpened. She worried that conception might take a long time because her cycles were unpredictable. She worried that the health improvements would slip away while they waited. She also felt guilty for measuring the possible cost of pregnancy before she was pregnant.

Her preconception clinician did not tell her that those feelings meant she was unready. The discussion returned to what could be observed over time and what remained unknown. Her history would be followed. Plans could change.

No one could promise the outcome she wanted.

In July 2025, Amara reached the end of the interval. She wrote the month in the notebook, underneath the line marking her last dose. She and her husband began trying to conceive.

Nothing looked different that morning.

Living without the next result

At ten weeks off the medication, Amara had gained five pounds. Her next cycle arrived later than she had hoped. She recorded both facts, then stopped weighing herself for a while because the number was becoming the first thing she thought about each morning.

That choice did not settle how she felt about her body. She missed the steadiness she had experienced on the medication, and she missed the sense that a treatment plan was moving toward a measurable result. Trying to conceive offered no similar schedule. There was a window each month, followed by waiting, followed by information that could disappoint her.

She was not pregnant yet when the follow-up lab slip appeared in her portal. Her A1C had risen to 5.8%. The primary care doctor described the change in the context of her longer record rather than as proof that she had undone her progress.

They agreed to continue monitoring while her pregnancy plans continued.

Amara copied the result into the notebook. She did not circle it.

Questions people ask

Why are

GLP-1 medications often stopped before pregnancy?

Human pregnancy information for GLP-1 medications remains limited, and product labeling advises against their use during pregnancy. The interval before trying to conceive differs among medications. In this story, the specialist reviewed the specific prescription and Amara’s history, then planned an eight-week pause.

Can

PCOS symptoms or health markers change after stopping a GLP-1?

They can change, but the pattern is not the same for everyone, and a change after stopping does not establish a single cause. Amara noticed earlier hunger, a later cycle, weight gain, and a higher A1C, while her clinicians interpreted those findings against years of records.

Is it normal to feel upset about stopping a helpful medication?

Amara felt grief and anger even though she wanted to try for pregnancy. Those feelings were not treated as evidence that she had made the wrong choice. The pause asked her to give up a source of stability without promising when she could return to it.

How did she cope with not knowing what would happen next?

She limited how often she weighed herself, kept appointments, and recorded changes without trying to explain each one. Some days the record reassured her; on others, it made the uncertainty louder. After entering the 5.8% A1C result, she set down her pen and closed the notebook.